Best deal of the week



Instruction for use: Xantinol nicotinate

I want this, give me price

Dosage form: Solution for intravenous and intramuscular administration, Solution for intramuscular injection, Substance-powder, tablets

Active substance: Xantinoli nicotinas


C04AD02 Xantinoli nicotinas

Pharmacological group



Angioprotectors and microcirculatory correctors


Correctors of cerebral circulation disorders

The nosological classification (ICD-10)

G43 Migraine: The pain of migraine; Migraine; hemiplegic migraine; Migraine headache; A migraine attack; Continuous headache; hemicranias

H35 Other retinal disease: retinal degeneration; Retinal degenerative changes in the eye; Subacute and chronic insufficiency of blood circulation in the retina or choroid

H81.0 Meniere's disease: Meniere's syndrome/ disease; Meniere's disease; Meniere's syndrome; Labyrinth dropsy; endolymphatic hydrops

I63 Cerebral infarction: ischemic Stroke; Ischemic brain disease; Ischemic stroke; Ischemic stroke and its consequences; Ischemic cerebral stroke; Ischemic cerebrovascular accident; Ischemic brain damage; Ischemic brain damage; ischemic conditions; Cerebral ischemia; Acute hypoxia brain; Acute cerebral ischemia; Acute ischemic cerebrovascular accident; Acute cerebral infarction; Acute ischemic stroke; Acute period of ischemic stroke; Focal cerebral ischemia; Ischemic stroke; recurrent stroke; The syndrome of Morgagni-Adams-Stokes; Chronic cerebral ischemia; cerebrovascular stroke; embolic stroke; Ischemic brain damage

I67.2 Cerebral atherosclerosis: Atherosclerosis of the arteries of the brain; Atherosclerosis of cerebral vessels; Atherosclerotic changes in cerebral vessels; Vascular diseases of the brain; Sclerotic ischemic attacks; Sclerosis of cerebral vessels

I70 Atherosclerosis: Atherosclerosis; Atherosclerosis of peripheral vessels; Atherosclerotic changes; Atherosclerotic vascular changes; Atherosclerotic disorders; spontaneous; Trombangioz obliterans; Frinlendera disease

I70.2 Atherosclerosis of arteries: arteriosclerosis obliterans; Arteriosclerosis peripheral arteries; Atherosclerosis of the arteries of the lower extremities; Atherosclerosis of peripheral arteries; Atherosclerosis limbs; Occlusive disease of the lower extremities; arteriosclerosis obliterans; Arteriosclerosis obliterans of lower limb arteries; Atherosclerosis obliterans of the upper limbs; Arteriosclerosis obliterans of lower extremities; Atherosclerosis of arteries; limb arteriopathy; Arteriosclerosis obliterans limbs; arteriosclerosis obliterans

I73.0 Raynaud's Syndrome: Raynaud's syndrome Leriche; Raynaud's disease; Raynaud's phenomenon; RaynaudLeriche syndrome; Raynaud's disease; Raynaud's syndrome with trophic disorders; Peripheral angiopathy

I74 Embolism and arterial thrombosis: Thrombosis of effort (stress); Arterial thrombosis; Arteriothrombosis; Subacute and chronic arterial thrombosis; Subacute thrombosis of peripheral arteries; Postoperative thrombosis; Vascular thrombosis; Vascular embolism; Thrombosis of aortocoronary shunt; Arterial thrombosis; Thrombosis of arteries; Coronary artery thrombosis; Coronary thrombosis; Thrombosis of blood vessels; Thrombosis with ischemic stroke; Thrombosis with general surgical operations; Thrombosis in Oncology Operations; Vascular thrombosis; Thrombus formation in the postoperative period; Thrombotic complications; Thromboembolic diseases; Thromboembolic syndrome; Thromboembolic complication in the postoperative period; Thromboembolism of arteries; Partial vascular thrombosis; Embolism; Embolism of arteries

I79.2 Peripheral angiopathy in diseases classified elsewhere: diabetic angiopathy; Angiopathy in diabetes; arteriosclerosis diabetic; Pain in lesions of peripheral nerves; Diabetic angiopathy; Diabetic microangiopathy; Diabetic vascular disease; Intermittent angioneurotic disbaziya; Macroangiopathy in diabetes; microangiopathy; Microangiopathy in diabetes mellitus; Tingling sensations in the hands and feet; Coldness in the extremities; Peripheral angiopathy; Peripheral arterial disease; Sclerosis Menkeberga; Chronic obliterating diseases of arteries

I80 Phlebitis and thrombophlebitis: Diseases of peripheral vessels; Inflammation of superficial veins; Inflammatory diseases of veins; Deep venous thrombophlebitis; The disease of veins; Disease of the veins of the lower extremities; Diseases of peripheral vessels; Migrating phlebitis; Insufficiency of veins of lower extremities; Exacerbation of chronic thrombophlebitis; Acute thrombophlebitis; Acute thrombophlebitis of superficial veins; Periphlebitis; Periflebit surface; Superficial inflammation of veins; Surface thrombophlebitis; Surface phlebitis; Thrombophlebitis; Deep vein thrombophlebitis; Thrombophlebitis superficial; Phlebitis; Phlebitis of deep veins; Phlebitis of superficial veins; Phlebopathy; Chronic thrombophlebitis; Endophlebitis

L87 Transepidermal perforations

L98.9 Skin and subcutaneous tissue disorders, unspecified: Adiponecrosisæ Atonic leatheræ Diseases of the skinæ Blisteræ Inflammatory disease of soft tissuesæ Inflammatory processes of epithelial tissuesæ Degenerative changes in the skin and mucous membranesæ Degenerative changes in the skin and mucous membranesæ Excess granulationæ Thinning of the skinæ Skin diseaseæ Maceration of the skinæ Minor skin lesionsæ Surface crack and skin abrasionæ Increased skin peelingæ Skin lesionæ Erosion of the skinæ Lipedemaæ Local non-infectious processes of skin and soft tissuesæ Disturbance of the structure of the skinæ Dysfunction of the skinæ Skin disorders

Composition and release form

1 tablet contains xanthinal nicotinate 150 mg; In blistere 10 pcs., In a cardboard bundle of 6 blisters.


Mode of action - Antiaggregational, vasodilating.

Interacts with adenosine receptors, blocks phosphodiesterase, increases the formation of cAMP, reduces the calcium content of smooth muscle, dilates the blood vessels.


Increases the delivery and utilization of oxygen by neurons of the central nervous system, reduces platelet aggregation, improves blood circulation and blood supply to the brain, microcirculation in the mesh shell of the eye.

Indications for Xantinol nicotinate

Obliterating endarteritis, atherosclerosis of the vessels of the lower limbs, intermittent claudication, Raynaud's disease, diabetic angiopathy, arterial thrombosis, retinopathy, trophic ulcers of the lower extremities, atherosclerotic disorders of the cerebral circulation, migraines, Meniere's syndrome, dermatoses, acute thrombophlebitis of the superficial and deep veins.

Contraindications for Xantinol nicotinate

Bleeding, myocardial infarction, congestive heart failure, peptic ulcer and duodenal ulcer, the first trimester of pregnancy.

Side effects

Dizziness, weakness, headache, fever, tingling and redness of the upper body, especially the head and neck.

Dosage and Administration

Inside, after eating, not chewing, - 1 (if necessary, 2-4) table. 3 times a day, for 2 months.

Precautionary measures

With caution (under the control of blood pressure) apply simultaneously with antihypertensive drugs.

Storage conditions of Xantinol nicotinate

In the dark place at room temperature.

Keep out of the reach of children.

Shelf life

3 years

Do not use beyond the expiration date printed on the package.

Someone from the Japan - just purchased the goods:
Pantogam 500mg 50 pills